DTB No 1: Olodaterol/Tiotropium. Spiolto Respimat®, Yanimo Respimat® for COPD

Content tools

Share it

The same efficacy at a higher price

Olodaterol/tiotropium offers a long-acting ß2-agonist in combination with a long-acting anticholinergic.
It has not been demonstrated to reduce the risk for COPD exacerbation.
No clinically relevant differences have been observed versus tiotropium alone either in lung function or in health-related quality of life in patients with moderate-to-severe COPD.
No comparative data are available of tiotropium vs. other LAMA/ LABA combinations.
Concerns have arisen on the cardiovascular safety profile. Patients with a history of cardiovascular events were excluded from trials.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *